首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
首頁 > 市場調查報告書 > 製藥 > 製藥企業 > 受託製造醫療藥品之機構（CMO）市場之展望：新興市場、關鍵研發企業、今後之動向
產業/市場分類
製藥 (4816)
肥胖症治療 (44)
非專利藥 (129)
疫苗 (181)
神經疾病 (172)
骨頭疾病治療 (37)
動物用醫藥 (17)
處方藥 (156)
規章 (126)
感染疾病 (346)
精神病 (84)
製藥企業 (524)
糖尿病 (191)
癌症 (909)
藥物開發 (1449)
DDS (182)
OTC 非處方藥 (150)
市場調查報告書

受託製造醫療藥品之機構（CMO）市場之展望：新興市場、關鍵研發企業、今後之動向

The Cmo Market Outlook: Emerging markets, key players and future trends

出版商 Business Insights
出版日期 2009年11月 商品編碼 103176
內容資訊 英文 98 pages
價格
本報告書已不再販售

本報告已在2012年02月29日停止出版。

更改為出版

CMO市場預測:∼2017年
The CMO Market Outlook to 2017
出版日期 : 2012年02月
商品編碼: 232972

簡介

因生產性低落與專利失效帶來壓力的增加，製藥企業不得不降低極為花費之大型製造設備之固定費。投資者為了節約成本，或以外包生產為彈性管理策略，轉向受託製造醫療藥品之機構（CMO）。另一方面，因受到大型合併必須重新檢討計畫所面臨之生產力過剩累積的威脅。

本報告將分析市場動態及推進、抑制之要因，評估市場構造。此外，將透過試論中國和印度外包訂貨廠商，來詳加檢證環境規制之變遷、專利保護等其他問題面臨之企業戰略。調查數據中也加上世界主要研究開發企業之評估與產業未來之展望，並並由下列摘要形式闡述。

實施概要

  • 受託製造市場
  • CMO市場分析
  • CMO市場相關新興區域
  • CMO市場關鍵研發企業
  • CMO市場之未來

第1章 受託製造市場

  • 摘要
  • 簡介
  • 現今市場推進之要因
    • 自家工廠之脫手
    • 外包所面臨加速而來之成本壓力
    • 開發產品數之增加
    • 製藥業界之重組
    • 生物醫療藥品市場的擴大
    • 新興醫療藥品市場之成長
  • 現今市場抑制之要因
    • 生產力過剩
    • 財務壓力
    • 愈漸激烈之競爭、低參與門檻
  • 結論

第2章 CMO市場分析

  • 摘要
  • 簡介
    • 一次生產
    • 二次生產
  • CMO市場構造
    • 中小型規模vs大規模CMO其分別之優勢
  • 産業戦略
    • 戰略性外包
    • 多様化
    • 戰略性外包
    • 生產力過剩
    • 實驗設備
  • 結論

第3章 CMO市場相關之新興區域

  • 摘要
  • 簡介
  • 中國
    • 中國受託製造市場推進之要因
    • 中國受託製造市場之課題
    • 在中國相關規範之架構
    • 智慧財產權之保護
    • 偽造藥品
    • 中國之主要受託製造機構
  • 印度
    • 印度CMO市場規模
    • 針對外國直接投資專利狀況之衝突
    • 被視為受歡迎之外國發包商印度
    • 印度CMO新興統合商務模式
    • 印度主要CMO之擴大戰略
  • 結論

第4章 CMO市場主要研發企業

  • Catalent
  • Lonza
  • Boehringer Ingelheim（BI）
  • DSM
  • Evonik
  • Patheon
  • Jubilant
  • BASF
  • Fareva
  • Wockhardt

第5章 CMO市場之未來

  • 摘要
  • 簡介
  • 戰略性合作關係
  • 生物藥劑生產
  • 海外採購
  • 市場展望

第6章 附錄

  • 參考文獻
  • 索引

圖表

目錄

Abstract

Falling productivity and patent expiries are placing increasing pressure on pharmaceutical companies to reduce fix costs including large manufacturing facilities. Sponsors are turning to CMOs in search of time and cost savings and as a way to flexibly manage outsourced manufacturing. Meanwhile the threat of overcapacity combined with inevitable program cancellations following mega-mergers resist the market. The CMO Market Outlook analyzes the market dynamics, drivers and resistors and assesses the structure of the market. China and India are discussed as destinations for outsourced manufacturing including analyses of regulatory changes and patent protection. Industry strategies are detailed and critically examined. Key players in the global, Chinese and Indian markets are also assessed. The industry trends are examined and used to map out the future of the industry including the impact on the landscape of players.

Table of Contents

Executive Summary

  • The contract manufacturing market
  • CMO market analysis
  • Emerging regions in the CMO market
  • Key players in the CMO market
  • The future of the CMO market

Chapter 1 The contract manufacturing market

  • Summary
  • Introduction
  • Current market drivers
    • Sale of captive plants
    • Cost pressures encourage outsourcing
    • Increasing number of products in development
    • Consolidation in the pharmaceutical industry
    • Increase in biopharmaceuticals market
    • Growth of emerging pharmaceutical markets
  • Current market restraints
    • Overcapacity
    • Financial pressures
    • Increased competition - low barriers to entry
    • Conclusions

Chapter 2 CMO market analysis

  • Summary
  • Introduction
    • Primary manufacturing
    • Secondary manufacturing
  • Structure of the CMO market
    • Advantages of small and medium sized vs. large CMOs
  • Industry strategies
    • Strategic outsourcing
    • Diversification
    • Biopharmaceutical manufacturing
    • Overcapacity
    • Pilot plants
  • Conclusion

Chapter 3 Emerging regions in the CMO market

  • Summary
  • Introduction
  • China
    • Drivers of the Chinese contract manufacturing market
    • Challenges of the Chinese contract manufacturing market
    • China' s regulatory framework
    • Intellectual property protection
    • Counterfeit drugs
    • China' s major contract manufacturing organizations
      • CMOs offering finished drugs services
      • Biopharmaceutical contract manufacturing in China
  • India
    • Size of the Indian CMO market
    • Patent situation and implications for foreign direct investment
      • Challenges in current patent law
    • India as a preferred offshoring destination
    • The new, integrated business model of Indian CMOs
      • Challenges facing the CRAMS business model
    • Expansion strategies of India' s major contract manufacturing organizations
    • Conclusions

Chapter 4 Key players in the CMO market

  • Summary
  • Introduction
  • Methodology
  • Catalent
    • Company profile
    • Business description
    • Partnering collaborations and recent deals
  • Lonza
    • Company profile
    • Business description
    • Partnering collaborations and recent deals
  • Boehringer Ingelheim (BI)
    • Company profile
    • Business description
    • Partnering collaborations and recent deals
  • DSM
    • Company profile
    • Business description
    • Partnering collaborations and recent deals
  • Evonik
    • Company profile
    • Business description
    • Partnering collaborations and recent deals
  • Patheon
    • Company profile
    • Business description
    • Partnering collaborations and recent deals
  • Jubilant
    • Company profile
    • Business description
    • Partnering collaborations and recent deals
  • BASF
    • Company profile
    • Business description
    • Partnering collaborations and recent deals
  • Fareva
    • Company profile
    • Business description
    • Partnering collaborations and recent deals
  • Wockhardt
    • Company profile
    • Business description
    • Partnering collaborations and recent deals

Chapter 5 The future of the CMO market

  • Summary
  • Introduction
  • Strategic partnerships
    • Biomanufacturing
    • Disposable equipment
    • Offshoring
    • Market outlook

Chapter 6 Appendix

  • Selected bibliography
  • Index

List of Figures

  • Figure 1.1: Contract manufacturing market ($bn), 2006-14e
  • Figure 1.2: Pharmaceutical manufacturing process
  • Figure 1.3: Services performed by CMOs and CDMOs
  • Figure 1.4: Number of FDA approvals (NCEs), 1990-2008
  • Figure 1.5: Number of products in development by phase, 1998-2009
  • Figure 1.6: The contract biomanufacturing market ($bn), 2009-14e
  • Figure 2.7: Stages of pharmaceutical manufacturing
  • Figure 2.8: Outsourced biological vs. non-biological manufacturing market, 2009-14e
  • Figure 2.9: Sponsors employing strategic outsourcing (%)
  • Figure 2.10: Installed bioreactor capacity (KL), 2006-13e
  • Figure 2.11: Geographical distribution of bioreactor capacity (%), 2008-13e
  • Figure 3.12: Share of pharmaceutical sales growth by region, 2006-09f
  • Figure 3.13: Chinese API exports, $bn 2007-14e
  • Figure 3.14: Chinese finished form pharmaceuticals exports 2007-14e, $bn
  • Figure 3.15: India' s finished dose exports ($bn), 2007-14e
  • Figure 3.16: India' s API exports ($bn), 2007-14e
  • Figure 3.17: Indian CRAMS market ($bn), 2007-14e
  • Figure 3.18: Three waves of Indian opportunity
  • Figure 5.19: Expectations of outsourcing expenditure change, 2009

List of Tables

  • Table 1.1: New entrants in the pharmaceutical CMO market
  • Table 2.2: Structure of the CMO industry
  • Table 2.3: Cost of inaccurate capacity planning
  • Table 3.4: Selected partnering agreements with Chinese manufacturers
  • Table 3.5: Selected contract manufacturing/ research deals in India
  • Table 3.6: Strategic options for Indian pharmaceutical companies
Back to Top